TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc BRIUMVI Call Transcript

Dec 29, 2022 / 01:30PM GMT
Release Date Price: €9.94 (+20.72%)
Operator

Greetings. Welcome to TG Therapeutics conference call and webcast. (Operator Instructions) Please note, this conference is being recorded. At this time, I'll now turn the conference over to your host, Jenna Bosco. Jenna, you may now begin.

Jenna Bosco
TG Therapeutics, Inc. - SVP of Corporate Communications

Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the U.S. Food and Drug Administration's approval of BRIUMVI are Michael Weiss, our Chairman and Chief Executive Officer; Dr. Lawrence Steinman of Stanford University; Dr. Bruce Cree of UCSF Weill Institute for Neurosciences; and Adam Waldman, our Chief Commercialization Officer. .

Mike will begin today's call by providing some introductory comments and context around the FDA approval of BRIUMVI, following which Dr. Steinman and Cree will share the data which supported the approval and provide an overview of the prescribing information. Lastly, Adam Waldman will join us to discuss our launch and commercialization plans before we turn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot